Core Viewpoint - Insilico Medicine has announced a collaboration with Kangji Medical Holdings to develop AI-powered innovative drugs targeting central nervous system and autoimmune diseases [1] Group 1: Collaboration Details - The partnership aims to leverage Insilico's validated AI platform and drug development capabilities alongside Kangji's experienced research team and deep understanding of disease areas [1] - The agreement includes the joint development of at least two research projects, with Insilico expected to receive up to tens of millions of Hong Kong dollars in research funding for each project [1] Group 2: Strategic Advantages - The collaboration is designed to maximize synergies in drug research, clinical development, and commercialization through resource integration and technological complementarity [1] - Insilico will utilize its Pharma.AI platform and expertise in target discovery, small molecule design, and optimization to enhance the efficient screening and validation of candidate molecules [1] - Kangji will contribute its extensive experience in clinical development strategy, regulatory pathway planning, clinical trial organization, and commercialization to facilitate the transition of projects from preclinical to clinical and market stages [1]
英矽智能：与康哲药业在中枢神经系统及自身免疫疾病领域多个项目上达成合作